Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Patient-profiled treatment responses in a large hypertension trial: a posthoc analysis of the INSIGHT study.

Journal of hypertension·2026
Same author

Resistant Hypertension Is Not Essential: It Is Primarily Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

EndoCompass Project: Research Roadmap for Adrenal and Cardiovascular Endocrinology.

Hormone research in paediatrics·2025
Same author

Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism.

The New England journal of medicine·2025
Same author

Voxel-Level Comparison of [<sup>18</sup>F]CETO and [<sup>11</sup>C]MTO for Molecular Imaging of Primary Aldosteronism.

Journal of nuclear medicine technology·2025
Same author

EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology.

European journal of endocrinology·2025
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Aliskiren es también conocido como Aliskiren.

Morris J Brown1

  • 1University of Cambridge, Cambridge, UK. m.j.brown@cai.cam.ac.uk

Circulation
|August 13, 2008
PubMed
Resumen
Este resumen es generado por máquina.

Aliskiren, un inhibidor oral de la renina, reduce efectivamente la presión arterial en dosis aprobadas con efectos secundarios mínimos. Se muestra prometedor como monoterapia o en combinación, particularmente para la hipertensión resistente.

Más Videos Relacionados

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Videos de Experimentos Relacionados

Last Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Área de la Ciencia:

  • Farmacología cardiovascular farmacología cardiovascular
  • Fisiología del sistema renal fisiología del sistema renal

Sus antecedentes:

  • El manejo de la hipertensión se basa en diversas clases de medicamentos.
  • El sistema renina-angiotensina-aldosterona (RAAS) es un regulador clave de la presión arterial.
  • La orientación de la renina ofrece un enfoque directo para la inhibición del RAAS.

Objetivo del estudio:

  • Para evaluar la eficacia y seguridad de aliskiren, un inhibidor directo de la renina.
  • Evaluar el papel de aliskiren en monoterapia y terapia de combinación para la hipertensión.
  • Explorar estrategias óptimas para la utilización de aliskiren en la práctica clínica.

Principales métodos:

  • Ensayos clínicos que evalúan la reducción de la presión arterial.
  • Evaluaciones de la relación dosis-respuesta en las dosis de 150 mg y 300 mg.
  • Análisis comparativo con otras clases de fármacos antihipertensivos.
  • Evaluaciones de seguridad y tolerabilidad frente al placebo.

Principales resultados:

  • Aliskiren demostró una reducción de la presión arterial relacionada con la dosis comparable a los antihipertensivos establecidos.
  • Los efectos adversos fueron similares a los del placebo.
  • Eficaz en monoterapia y en regímenes de combinación.
  • Se observó un mayor beneficio cuando se combina con agentes natriuréticos, pero el doble bloqueo de renina también mostró beneficios.

Conclusiones:

  • Aliskiren es un agente antihipertensivo oral seguro y eficaz.
  • Ofrece una valiosa opción para pacientes con hipertensión no controlada o intolerante.
  • Comprender el sistema de renina puede optimizar el valor terapéutico del aliskiren.
  • Se necesitan más estudios de resultados para determinar los beneficios cardiovasculares no relacionados con la presión arterial.